Alnylam Pharmaceuticals 株価情報 (NASDAQ: ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) 株価情報

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Large Cap

News

Movers

ALNY

CVNA

FTAI

MSTR

RDDT

RIVN

過去1週間でこれらの10本の大型株は最も良いパフォーマンスを発揮しました。投資ポートフォリオには含まれていますか？Rivian Automotive, Inc. (NASDAQ:RIVN)の株は、同社が生産を単純化し、コストを削減し、フォルクスワーゲンとの 合弁事業を発表したという報告書に続き、先週30.04％急騰しました。

過去1週間の大型株を特集　米国市場での存在感は

Equities

Markets

AFRM

NVDA

TSLA

月曜日、米国の主要株価指数は反発しました。ダウ平均株価は0.7％以上の上昇で39,411.21ドルで終了し、一方でS&amp;P500は0.3％減の5,447.87ドルでした。ナスダックは約1.1％減の17,496.82でした。

Nvidiaが米国の主要株価指数を牽引　

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies raised Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) price target from $105 to $118. Jefferies analyst David Katz upgraded the stock from Hold to Buy. Wynn Resorts shares closed at $88.82 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/WYNN/analyst-ratings">view </a>this stock.</li>
<li>Keefe, Bruyette &amp; Woods increased the price target for Brighthouse Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) from $60 to $66. Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintained a Market Perform rating. Brighthouse Financial shares closed at $62.14 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/BHF/analyst-ratings">view </a>this stock.</li>
<li>Morgan Stanley raised Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) price target from $42 to $60. Morgan Stanley analyst Craig Hettenbach downgraded the stock from Overweight to Equal-Weight. Hims &amp; Hers Health shares closed at $60.47 on Friday. See how other <a href="https://www.benzinga.com/quote/HIMS/analyst-ratings">analysts </a>view this stock.</li>
<li>Needham raised the price target for DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) from $60 to $65. Needham analyst Bernie McTernan maintained a Buy rating. DraftKings shares closed at $53.49 on Friday. <a href="https://www.benzinga.com/quote/DKNG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised the price target for Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from $41 to $47. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Bath &amp; Body Works shares closed at $36.47 on Friday. <a href="https://www.benzinga.com/quote/BBWI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Outlook Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) price target from $30 to $3. HC Wainwright &amp; Co. analyst Douglas Tsao maintained a Buy rating. Outlook Therapeutics shares settled at $1.87 on Friday. <a href="https://www.benzinga.com/quote/OTLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $384 to $385. Canaccord Genuity analyst Whitney Ijem maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $256.45 on Friday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) price target from $255 to $305. Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained a Market Perform rating. Coinbase shares closed at $274.31 on Friday.  <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut the price target for Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) from $155 to $150. B of A Securities analyst Wamsi Mohan maintained a Buy rating. Dell shares settled at $114.38 on Friday. <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank cut Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) price target from $128 to $105. Deutsche Bank analyst James Shin downgraded the stock from Buy to Hold. Merck shares closed at $83.01 on Friday. <a href="https://www.benzinga.com/quote/mrk/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>

Price Target

Pre-Market Outlook

Analyst Ratings

BBWI

Brighthouse Financial, Inc. - Common Stock

COIN

DELL

DKNG

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OTLK

WYNN

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $384 to $385.

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $385

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Equal-Weight and raises the price target from $275 to $284.

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $284

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

Reiteration

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

Guidance

Alnylam Sees 2024 Total TTR Net Product Revenues $1.6B-$1.725B

Earnings

Alnylam Pharmaceuticals Q4 2024 Adj. EPS $0.06, Sales $593.166M Beat $583.791M Estimate

ABNB

AENT

AGIO

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

CROX

CYBR

DDOG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

In the latest quarter, 7 analysts provided ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Alnylam Pharmaceuticals and provided 12-month price targets. The average target is $332.29, accompanied by a high estimate of $400.00 and a low estimate of $296.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.17%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739300431_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Alnylam Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$296.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Alnylam Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Alnylam Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Alnylam Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -33.26%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -22.27%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -761.91%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.72%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 40.24. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Views

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 5.7% since its last report. The company recently reported that it has 3.15 million shares sold short, which is 2.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739219412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Alnylam Pharmaceuticals's Recent Short Interest

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.34% on an annualized basis producing an average annual return of 20.61%. Currently, Alnylam Pharmaceuticals has a market capitalization of $36.14 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth $16,726.61 today based on a price of $280.16 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738274415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 4.18% since its last report. The company recently reported that it has 3.35 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737032452_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 7.96% on an annualized basis producing an average annual return of 19.36%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.31 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth $14,221.92 today based on a price of $258.27 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736802908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

WIIM

Alnylam Pharmaceuticals shares are trading higher. The company reported preliminary results.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.2, a high estimate of $400.00, and a low estimate of $296.00. This current average has increased by 2.93% from the previous average price target of $326.64. 
<img src="https://www.benzinga.com/files/images/story/2025/1736769643_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$296.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$310.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$329.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$366.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$371.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$305.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Alnylam Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>A Deep Dive into Alnylam Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Alnylam Pharmaceuticals faced challenges, resulting in a decline of approximately -33.26% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -22.27%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -761.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.72%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 40.24. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

<ul>
<li>– Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO&#xAE;, AMVUTTRA&#xAE;, GIVLAARI&#xAE;, and OXLUMO&#xAE;, Representing 33% Annual Growth –</li>
<li>– 2025 Combined Net Product Revenue Guidance&#x2A;&#x2A; of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P5x25 Goal of Non-GAAP Profitability –</li>
<li>– Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth –</li>
</ul>

Reported Earlier, Alnylam Pharmaceuticals Preliminary Results: $1.6B In 2024 Net Product Revenue (+33% YoY); 2025 Revenue Guidance Of $2.05B–$2.25B, And Highlights Key Pipeline Goals

Bernstein analyst William Pickering maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and lowers the price target from $314 to $310.

Bernstein Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $310

Press Releases

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

GIVLAARI® (givosiran injection) Now Widely Reimbursed in Canada For the Treatment of Acute Hepatic Porphyria (AHP) in Adults

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

Comments

Alnylam Pharmaceuticals

ニュース

パートナーシップ

ベンジンガ・グローバル